Jennifer Bergstrom1, Alessia Aloisi2, Shannon Armbruster3, Ting-Tai Yen1, Jvan Casarin4, Mario M Leitao5, Edward J Tanner1, Rayna Matsuno6, Karime Kalil Machado1, Sean C Dowdy4, Pamela T Soliman3, Stephanie L Wethington1, Rebecca L Stone1, Kimberly L Levinson1, Amanda N Fader7. 1. Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medicine, Baltimore, MD, USA. 2. Department of Gynecologic Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Division of Gynecologic Oncology, Mayo Clinic, Rochester, MN, USA. 5. Department of Gynecologic Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY, USA. 6. Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA. 7. Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medicine, Baltimore, MD, USA. Electronic address: afader1@jhmi.edu.
Abstract
OBJECTIVES: Minimally invasive surgery (MIS) is a quality measure for endometrial cancer (EC) established by the Society of Gynecologic Oncology and the American College of Surgeons. Our study objective was to assess the proportion of EC cases performed by MIS at National Comprehensive Cancer Network (NCCN) centers and evaluate perioperative outcomes. METHODS: A retrospective cohort study of women who underwent surgical treatment for EC from 2013 to 2014 was conducted at four NCCN centers. Multivariable mixed logistic regression models analyzed factors associated with failure to perform MIS and perioperative complications. RESULTS: In total 1621 patients were evaluated; 86.5% underwent MIS (robotic-assisted 72.5%, laparoscopic 20.9%, vaginal 6.6%). On multivariable analysis, factors associated with failure to undergo MIS were uterine size >12cm (Odds Ratio [OR]: 0.17, 95% CI 0.03-0.9), stage III (OR: 0.16, 95% CI 0.05-0.49) and IV disease (OR: 0.07, 95% CI 0.02-0.22). For stage I/II disease, complications occurred in 5.1% of MIS and 21.7% of laparotomy cases (p<0.01). Laparotomy was associated with increases in any complication (OR: 6.0, 95% CI 3.3-10.8), gastrointestinal (OR: 7.2, 95% CI 2.6-19.5), wound (OR: 3.7, 95% CI 1.5-9.2), respiratory (OR 37.5, 95% CI 3.9-358.0), VTE (OR 10.5, 95% CI 1.3-82.8) and 30-day readmission (OR: 2.6, 95% CI 1.4-4.9) compared to MIS. CONCLUSIONS: At NCCN-designated centers, the MIS hysterectomy rate in EC is higher than the published national average, with low perioperative complications. Previously identified disparities of age, race, and BMI were not observed. A proposed MIS hysterectomy benchmark of >80% in EC care is feasible when performed at high volume centers.
OBJECTIVES: Minimally invasive surgery (MIS) is a quality measure for endometrial cancer (EC) established by the Society of Gynecologic Oncology and the American College of Surgeons. Our study objective was to assess the proportion of EC cases performed by MIS at National Comprehensive Cancer Network (NCCN) centers and evaluate perioperative outcomes. METHODS: A retrospective cohort study of women who underwent surgical treatment for EC from 2013 to 2014 was conducted at four NCCN centers. Multivariable mixed logistic regression models analyzed factors associated with failure to perform MIS and perioperative complications. RESULTS: In total 1621 patients were evaluated; 86.5% underwent MIS (robotic-assisted 72.5%, laparoscopic 20.9%, vaginal 6.6%). On multivariable analysis, factors associated with failure to undergo MIS were uterine size >12cm (Odds Ratio [OR]: 0.17, 95% CI 0.03-0.9), stage III (OR: 0.16, 95% CI 0.05-0.49) and IV disease (OR: 0.07, 95% CI 0.02-0.22). For stage I/II disease, complications occurred in 5.1% of MIS and 21.7% of laparotomy cases (p<0.01). Laparotomy was associated with increases in any complication (OR: 6.0, 95% CI 3.3-10.8), gastrointestinal (OR: 7.2, 95% CI 2.6-19.5), wound (OR: 3.7, 95% CI 1.5-9.2), respiratory (OR 37.5, 95% CI 3.9-358.0), VTE (OR 10.5, 95% CI 1.3-82.8) and 30-day readmission (OR: 2.6, 95% CI 1.4-4.9) compared to MIS. CONCLUSIONS: At NCCN-designated centers, the MIS hysterectomy rate in EC is higher than the published national average, with low perioperative complications. Previously identified disparities of age, race, and BMI were not observed. A proposed MIS hysterectomy benchmark of >80% in EC care is feasible when performed at high volume centers.
Authors: Jeffrey J Leow; Eugene K Leong; Emily C Serrell; Steven L Chang; Russell L Gruen; Keng Siang Png; Lisa T Beaule; Quoc-Dien Trinh; Mani M Menon; Jesse D Sammon Journal: Eur Urol Focus Date: 2017-04-06
Authors: Monika Janda; Val Gebski; Alison Brand; Russel Hogg; Thomas W Jobling; Russel Land; Tom Manolitsas; Anthony McCartney; Marcelo Nascimento; Deborah Neesham; James L Nicklin; Martin K Oehler; Geoff Otton; Lewis Perrin; Stuart Salfinger; Ian Hammond; Yee Leung; Tom Walsh; Peter Sykes; Hextan Ngan; Andrea Garrett; Michael Laney; Tong Yow Ng; Karfai Tam; Karen Chan; C David H Wrede; Selvan Pather; Bryony Simcock; Rhonda Farrell; Andreas Obermair Journal: Lancet Oncol Date: 2010-07-16 Impact factor: 41.316
Authors: Robert E Bristow; Matthew A Powell; Noor Al-Hammadi; Ling Chen; J Philip Miller; Phillip Y Roland; David G Mutch; William A Cliby Journal: J Natl Cancer Inst Date: 2013-03-28 Impact factor: 13.506
Authors: John K Chan; Mallory Zhang; Jessica M Hu; Jacob Y Shin; Kathryn Osann; Daniel S Kapp Journal: J Surg Oncol Date: 2008-02-01 Impact factor: 3.454
Authors: Alice B Kornblith; Helen Q Huang; Joan L Walker; Nick M Spirtos; Jacob Rotmensch; David Cella Journal: J Clin Oncol Date: 2009-10-05 Impact factor: 44.544
Authors: Francesco Multinu; Jvan Casarin; Serena Cappuccio; Gary L Keeney; Gretchen E Glaser; William A Cliby; Amy L Weaver; Michaela E McGree; Stefano Angioni; Gavino Faa; Mario M Leitao; Nadeem R Abu-Rustum; Andrea Mariani Journal: Gynecol Oncol Date: 2019-05-22 Impact factor: 5.482
Authors: Peter A Argenta; Jordan Mattson; Colleen L Rivard; Elizabeth Luther; Alexandra Schefter; Rachel I Vogel Journal: Gynecol Oncol Date: 2022-03-18 Impact factor: 5.304
Authors: Francesco Multinu; Jennifer A Ducie; Ane Gerda Zahl Eriksson; Brooke A Schlappe; William A Cliby; Gretchen E Glaser; Tommaso Grassi; Gary L Keeney; Amy L Weaver; Nadeem R Abu-Rustum; Mario M Leitao; Andrea Mariani Journal: Gynecol Oncol Date: 2019-10-08 Impact factor: 5.482
Authors: Christer Borgfeldt; Erik Holmberg; Janusz Marcickiewicz; Karin Stålberg; Bengt Tholander; Elisabeth Åvall Lundqvist; Angelique Flöter-Rådestad; Maria Bjurberg; Pernilla Dahm-Kähler; Kristina Hellman; Elisabet Hjerpe; Preben Kjölhede; Per Rosenberg; Thomas Högberg Journal: BMC Cancer Date: 2021-06-02 Impact factor: 4.430